News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
225,170 Results
Type
Article (5014)
Company Profile (17)
Press Release (220139)
Section
Business (82198)
Career Advice (461)
Deals (15041)
Drug Delivery (8)
Drug Development (19061)
Employer Resources (30)
FDA (3676)
Job Trends (3901)
News (120101)
Policy (7501)
Tag
2024 BioCapital Digital (2)
2024 Biotech Beach Standard (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (292)
Accelerated approval (2)
Adcomms (3)
Allergies (9)
Alliances (14771)
ALS (20)
Alzheimer's disease (247)
Antibody-drug conjugate (ADC) (11)
Approvals (3693)
Artificial intelligence (41)
Autoimmune disease (3)
Automation (3)
Bankruptcy (97)
Best Places to Work (2862)
Biosimilars (11)
Biotechnology (21)
Bladder cancer (9)
Brain cancer (7)
Breast cancer (48)
Cancer (445)
Cardiovascular disease (24)
Career advice (393)
Career pathing (3)
CAR-T (31)
Cell therapy (102)
Cervical cancer (2)
Clinical research (16027)
Collaboration (169)
Compensation (169)
Complete response letters (2)
COVID-19 (301)
CRISPR (7)
C-suite (104)
Cystic fibrosis (16)
Data (512)
Depression (5)
Diabetes (42)
Diagnostics (2040)
Digital health (3)
Diversity, equity & inclusion (12)
Drug discovery (15)
Drug pricing (6)
Drug shortages (1)
Duchenne muscular dystrophy (11)
Earnings (40821)
Editorial (2)
Employer branding (6)
Employer resources (31)
Events (37759)
Executive appointments (311)
FDA (3927)
Featured Employer (6)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (185)
Gene editing (15)
Generative AI (2)
Gene therapy (50)
GLP-1 (108)
Government (411)
Guidances (17)
Healthcare (5035)
Huntington's disease (1)
IgA nephropathy (4)
Immunology and inflammation (13)
Indications (6)
Infectious disease (317)
Inflammatory bowel disease (24)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (15)
Interviews (53)
IPO (7822)
IRA (3)
Job creations (1121)
Job search strategy (360)
Kidney cancer (7)
Labor market (5)
Layoffs (100)
Leadership (5)
Legal (2332)
Liver cancer (17)
Lung cancer (54)
Lymphoma (31)
Management (10)
Manufacturing (49)
MASH (28)
Medical device (3859)
Medtech (3860)
Mergers & acquisitions (7424)
Metabolic disorders (122)
Multiple sclerosis (8)
NASH (6)
Neurodegenerative disease (9)
Neuropsychiatric disorders (1)
Neuroscience (340)
NextGen: Class of 2025 (1674)
Non-profit (727)
Northern California (926)
Now hiring (3)
Obesity (53)
Opinion (30)
Ovarian cancer (17)
Pain (12)
Pancreatic cancer (14)
Parkinson's disease (27)
Partnered (4)
Patents (21)
Patient recruitment (29)
Peanut (5)
People (24589)
Pharmaceutical (5)
Pharmacy benefit managers (1)
Phase I (4776)
Phase II (6961)
Phase III (5547)
Pipeline (552)
Policy (9)
Postmarket research (625)
Preclinical (1868)
Press Release (66)
Prostate cancer (27)
Psychedelics (3)
Radiopharmaceuticals (105)
Rare diseases (67)
Real estate (1874)
Recruiting (8)
Regulatory (5113)
Reports (14)
Research institute (301)
Resumes & cover letters (68)
Rett syndrome (3)
Schizophrenia (21)
Series A (28)
Series B (23)
Sickle cell disease (7)
Southern California (699)
Special edition (1)
Spinal muscular atrophy (28)
Sponsored (4)
Startups (1008)
Stomach cancer (1)
Supply chain (10)
Tariffs (4)
United States (7028)
Vaccines (36)
Venture capitalists (2)
Weight loss (21)
Women's health (1)
Date
Today (36)
Last 7 days (169)
Last 30 days (735)
Last 365 days (9983)
2025 (2987)
2024 (11029)
2023 (13193)
2022 (18658)
2021 (19678)
2020 (18238)
2019 (13205)
2018 (10205)
2017 (10001)
2016 (9157)
2015 (12119)
2014 (9588)
2013 (7707)
2012 (8329)
2011 (8796)
2010 (8634)
Location
Africa (184)
Alabama (13)
Alaska (2)
Arizona (59)
Arkansas (1)
Asia (11455)
Australia (1608)
California (1941)
Canada (698)
China (71)
Colorado (82)
Connecticut (91)
Delaware (29)
Europe (24510)
Florida (274)
Georgia (33)
Idaho (23)
Illinois (112)
India (7)
Indiana (64)
Iowa (1)
Japan (72)
Kansas (24)
Kentucky (10)
Louisiana (5)
Maine (40)
Maryland (221)
Massachusetts (1552)
Michigan (85)
Minnesota (139)
Mississippi (1)
Missouri (23)
Montana (16)
Nebraska (12)
Nevada (23)
New Hampshire (15)
New Jersey (558)
New Mexico (5)
New York (470)
North Carolina (326)
North Dakota (2)
Northern California (926)
Ohio (56)
Oklahoma (5)
Oregon (4)
Pennsylvania (345)
Puerto Rico (1)
Rhode Island (13)
South America (276)
South Carolina (5)
Southern California (699)
Tennessee (40)
Texas (229)
Utah (60)
Virginia (46)
Washington D.C. (9)
Washington State (174)
West Virginia (2)
Wisconsin (22)
225,170 Results for "microbion corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Microbion Receives Award at Advanced Wound Care Summit USA’s Innovation Showcase
Microbion Corporation announced that the company won the Advanced Wound Care Summit’s Innovation Showcase award.
April 25, 2024
·
4 min read
Microbion Selected to Present at Advanced Wound Care Summit USA
Microbion Corporation today announced that the company has been selected to present topical pravibismane for the treatment of diabetic foot infection (DFI) at the Advanced Wound Care Summit USA held at the Boston Marriot Long Wharf from April 16th to 17th.
April 15, 2024
·
3 min read
Drug Development
Microbion’s Topical Pravibismane Phase 1b Moderate or Severe Diabetic Foot Ulcer Infection Study is Published in International Wound Journal
Microbion Corporation today announced that the company has published results from its topical pravibismane Phase 1b study in the peer-reviewed International Wound Journal.
April 4, 2024
·
6 min read
BioForest
Microbion CEO to Participate in Panel Discussion at BioFuture 2023
Microbion Corporation announced that Karim Lalji, CEO, will participate in a panel discussion during BioFuture 2023.
October 5, 2023
·
4 min read
FDA
Microbion’s Pravibismane Granted Second FDA Orphan Drug Designation for the Treatment of Non-tuberculous Mycobacterial (NTM) Infections
Microbion Corporation today announced that the company has been granted a second orphan drug designation for its lead drug candidate, pravibismane, for the treatment of non-tuberculous mycobacterial (NTM) infections.
January 30, 2024
·
4 min read
Microbion Corporation CEO to Present at the 2023 BIO CEO & Investor Conference
Microbion Corporation, a clinical stage pharmaceutical company, announced that Karim Lalji, CEO of Microbion Pharma Corp., will be presenting at the 2023 BIO CEO & Investor Conference in New York, NY.
February 3, 2023
·
2 min read
Microbion Corp. Granted US Patent for the Use of Inhaled Pravibismane for Pulmonary Infections
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,464,749 to Microbion with claims to the use of Microbion’s proprietary pravibismane inhaled composition for treatment of pulmonary infections.
April 4, 2023
·
3 min read
Microbion Presented New Pravibismane Data Against Mycobacteroides abscessus at the 6th World Bronchiectasis and NTM Conference
Microbion Corporation today announced that the company presented a poster highlighting the results from a series of in vitro and in vivo studies characterizing pravibismane’s effect against Mycobacteroides abscessus at the recent 6th World Bronchiectasis & NTM Conference held in New York, NY.
August 15, 2023
·
4 min read
Microbion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of Pravibismane
Microbion Corporation announced that the US Patent and Trademark Office issued to Microbion, United States Patent No. 11,324,715 on May 10, 2022, with claims to a pharmaceutical composition of pravibismane.
October 4, 2022
·
3 min read
Drug Development
Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic Foot Infections
Microbion Corporation today announced that a Phase 2, randomized, controlled study has been initiated to assess the safety and efficacy of topical pravibismane for the treatment of subjects with moderate infections of chronic diabetic foot ulcers (DFU).
March 9, 2023
·
7 min read
1 of 22,517
Next
